The genome-editing technology CRISPR has raced from the lab to the bedside, but the biotech companies translating the revolutionary tool into human medicine say they’re not cutting corners or ignoring the ethical implications of rewriting human life.
“Something that, for me, inspires hesitation and pause is that when you edit someone, in some respects, that’s forever,” said Dr. John Leonard, CEO of Intellia Therapeutics, at a STAT Plus event on the future of CRISPR. [Two videos below capture Thursday night’s panel discussions.]
“That risk should definitely be worth it,” Leonard said.
About the Author Reprints
